FDA Approves New Targeted Treatment for Relapsed or Refractory Acute Myeloid Leukemia.
The U.S. Food and Drug Administration has approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for patients with relapsed or refractory AML who have specific mutations in the IDH2 gene. AML is a rapidly progressing cancer […]
FDA Approves New Targeted Treatment for Relapsed or Refractory Acute Myeloid Leukemia. Read More »
